Please use this identifier to cite or link to this item:
Title: Gel Formulations with an Echinocandin for Cutaneous Candidiasis: The Influence of Azone and Transcutol on Biopharmaceutical Features
Author: Pérez-González, Noelia
Espinoza, Lupe Carolina
Rincón, María
Sosa Díaz, Lilian Elisa
Mallandrich Miret, Mireia
Suñer Carbó, J. (Joaquim)
Bozal de Febrer, Núria
Calpena Campmany, Ana Cristina
Clares Naveros, Beatriz
Keywords: Candidiasi
Emulsions (Farmàcia)
Gels (Farmàcia)
Emulsions (Pharmacy)
Gels (Pharmacy)
Issue Date: 6-Apr-2023
Abstract: Abstract: Caspofungin is a drug that is used for fungal infections that are difficult to treat, including invasive aspergillosis and candidemia, as well as other forms of invasive candidiasis. The aim of this study was to incorporate Azone in a caspofungin gel (CPF-AZ-gel) and compare it with a promoter-free caspofungin gel (CPF-gel). An in vitro release study using a polytetrafluoroethylene membrane and ex vivo permeation into human skin was adopted. The tolerability properties were confirmed by histological analysis, and an evaluation of the biomechanical properties of the skin was undertaken. Antimicrobial efficacy was determined against Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis. CPF-AZ-gel and CPF-gel, which had a homogeneous appearance, pseudoplastic behavior, and high spreadability, were obtained. The biopharmaceutical studies confirmed that caspofungin was released following a one-phase exponential association model and the CPF-AZ gel showed a higher release. The CPF-AZ gel showed higher retention of caspofungin in the skin while limiting the diffusion of the drug to the receptor fluid. Both formulations were well-tolerated in the histological sections, as well as after their topical application in the skin. These formulations inhibited the growth of C. glabrata, C. parapsilosis, and C. tropicalis, while C. albicans showed resistance. In summary, dermal treatment with caspofungin could be used as a promising therapy for cutaneous candidiasis in patients that are refractory or intolerant to conventional antifungal agents.
Note: Reproducció del document publicat a:
It is part of: Gels, 2023, vol. 9, num. 308, p. 1-24
Related resource:
ISSN: 2310-2861
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
733225.pdf10.65 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons